


Publications of the Week
Antibody Interference by a Non-Neutralizing Antibody Abrogates Humoral Protection against *Plasmodium yoelii* Liver Stage

First Author: Kamalakannan Vijayan | Senior Authors: Alexis Kaushansky (pictured, left) and Noah Sather (right) | Cell Reports | Seattle Children's Research Institute, UW, and Brotman Baty Research Institute



The authors demonstrate proof of concept that non-neutralizing antibodies (nAbs) can alter the efficacy of malaria vaccination by using a rodent malaria model in which nAbs can directly interfere with protective anti-circumsporozoite protein (CSP) humoral responses. They characterize a monoclonal antibody, RAM1, against *Plasmodium yoelii* sporozoite major surface antigen CSP. [Profile](#) | [Abstract](#)

Integrative Oncogene-Dependency Mapping Identifies RIT1 Vulnerabilities and Synergies in Lung Cancer

First Authors: Athea Vichas and Amanda Riley | Senior Author: Alice Berger (pictured) | Nature Communications | Fred Hutch and UW



To identify opportunities for therapeutic intervention in other rarer subsets of cancer, the authors investigate the oncogene-specific dependencies conferred by the lung cancer oncogene, *RIT1*. Combining genetic data with small-molecule sensitivity profiling, they identify a unique vulnerability of *RIT1*-mutant cells to loss of spindle assembly checkpoint regulators. [Abstract](#) | [Press Release](#)

A Rationally Designed C-Di-AMP FRET Biosensor to Monitor Nucleotide Dynamics

First Author: Alex Pollock | Senior Author: Joshua Woodward (pictured) | Journal of Bacteriology | UW



Crystallization of the *Listeria monocytogenes* c-di-AMP effector protein Lmo0553 enabled structure guided design of a Förster resonance energy transfer (FRET) based biosensor, which the authors have named CDA5. They identify a distribution of c-di-AMP in *Bacillus subtilis* populations first grown in Luria Broth and then resuspended in diluted Luria Broth compatible with fluorescence analysis. [Abstract](#)

[View All Publications](#)
Local News
Antibody Findings Spark Ideas for Pan-Coronavirus Vaccine

UW Medicine



Virus researchers are determined to discover a means to broadly safeguard people from the continuing threat of emerging coronaviruses. A new study in the journal *Science* describes research on five such human monoclonal antibodies that can cross-react with a number of beta-coronaviruses. These antibodies target a structure, called stem helix, in the spike protein of these viruses. The spike protein is critical to the virus' ability to overtake host cells. [Read More](#)

Lumen Bioscience Teams with Google to Apply Machine Learning to Biologics Manufacturing

Lumen Bioscience



Lumen Bioscience announced the results of a research collaboration with Google that applied machine learning to significantly advance the scalability of spirulina-based biologic drugs. The company simultaneously announced receipt of \$2 million in additional grant funding from the Department of Energy to support further development of these research findings. [Read More](#)

Eliem Is Latest Seattle-Area Biotech to Go Public, Raises \$80M to Help Fuel Treatments for Nervous System Disorders

GeekWire



Eliem Therapeutics, led by former Juno Therapeutics executive Bob Azelby (pictured), is the latest biotech company from Washington state to go public. In the past 12 months, eight other biotech companies from the state have priced IPOs or gone public via special purpose acquisition companies. Still in the early stages of development, Eliem is targeting its technologies to areas such as chronic pain, psychiatry, epilepsy and other disorders related to the central nervous system. [Read More](#)

Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin

Seagen



Seagen and RemeGen announced that they have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted antibody-drug conjugate. "This collaboration leverages Seagen's world-class expertise and knowledge of ADC development, manufacturing and commercialization to maximize the potential of disitamab vedotin," said Dr. Clay Siegall (pictured), President and CEO of Seagen. [Read More](#)

A Life Sciences Startup Will Base Its Headquarters in Both Seattle and California. It's Far from the Only One

The Seattle Times



Sonoma Biotherapeutics, a life sciences company developing treatments for autoimmune diseases, announced this week it raised \$265 million to grow its operations in Seattle and the San Francisco Bay Area. Having labs in two biotechnology hubs, coupled with the recent funding, will help Sonoma continue its research with new and existing products. [Read More](#)

Kineta Announces Patent Issuance for US Patent Covering Composition of Matter of KCP506, a Novel Non-Opioid Therapy for Chronic Pain


BioSpace



Kineta announced that the company has received Patent No. 11,014,970 for *Modifications and Uses of Conotoxin Peptides* from the US Patent and Trademark Office related to KCP506, the company's novel non-opioid therapy in development to treat chronic neuropathic pain. KCP506 may potentially be an effective treatment for many types of chronic neuropathic pain including radiculopathy, chemotherapy-induced peripheral neuropathy, and diabetic neuropathy. [Read More](#)

Curebase, Adaptive Biotechnologies Announce Collaboration to Expand Clinical Study Access

Curebase via Precision Newswire



Curebase and Adaptive Biotechnologies announced an ongoing research collaboration to broaden patient participation in Adaptive's clinical studies. The initial two studies of the partnership involve Adaptive's T-Detect™ diagnostic test. T-Detect™ is under development for multiple diseases translating the natural diagnostics capability of T-cells into clinical practice. [Read More](#)

Researchers Pinpoint 'Correlates of Protection' for Moderna Vaccine

Fred Hutch



A group of top scientists, including Dr. Peter Gilbert, a biostatistician at Seattle's Fred Hutch, are reporting that they have defined correlates of protection for the widely used Moderna mRNA vaccine. Correlates of protection are laboratory-derived numbers that are widely used to measure performance and update vaccines against dozens of common diseases ranging from whooping cough to influenza. [Read More](#)

[View All Articles](#) | [Submit an Article](#)
Upcoming Events in Seattle

August 17 12:00 PM	Increasing Black, Indigenous and People of Color Participation in Research Online
August 17 5:00 PM	A Celeb-Studded Event to Support Research Paramount Theatre
August 19 4:30 PM	Life Science Washington Annual Summer Social Conference Center
August 23 11:00 AM	Basic Cardiovascular Sciences Scientific Sessions 2021 Online
September 7 3:00 PM	VIDD Scientific Seminar Series Online

[View All Events](#) | [Submit an Event](#)
Science Jobs in Seattle

- Quality Assurance Associate**
Seattle Cancer Care Alliance
- Scientist, Senior Scientist, or Principal Scientist, Machine Learning**
A-Alpha Bio
- Director, CMC Quality Assurance**
OncoResponse
- Associate Scientist, NGS Sequencing, Molecular Biology**
Bristol Myers Squibb
- Clinical Program Manager**
Gilead Sciences

[View 150 Other Science Jobs](#) | [Submit a Job](#)

 Submit your articles and events by reaching out to us at info@scienceinseattle.com.

BROUGHT TO YOU BY



- STEMCELL Technologies**
Products | Services
- STEMCELL Science News**
Free Weekly Updates on Your Field
- The Stem Cell Podcast**
Interviews and Updates on Stem Cell Science